Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.

Frontiers in immunology - 1 Jan 2021

Shrestha Lok Bahadur, Tedla Nicodemus, Bull Rowena A

Abstract excerpt

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have become a major concern in the containment of current pandemic. The variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta) have shown reduced sensitivity to monoclonal antibodies, plasma and/or sera obtained from convalescent patients and vaccinated individuals. Development of potent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral
Share to Antibody Specificity
Share to Binding Sites, Antibody

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Broadly Neutralizing Antibodies

Share to COVID-19

Share to Cross Reactions

Share to Host-Pathogen Interactions

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 34646276
DOI: 10.3389/fimmu.2021.752003
PMCID: PMC8502962

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.PMID 34646276Read ↗

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikeSemantic proximity Read ↗

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read ↗

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read ↗

Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infectionSemantic proximity Read ↗

Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domainSemantic proximity Read ↗

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe diseaseSemantic proximity Read ↗

Cross-Neutralizing Monoclonal Antibodies with Broad Activity Against Human and Bat-Derived SARS-Related CoronavirusesSemantic proximity Read ↗

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsSemantic proximity Read ↗

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesSemantic proximity Read ↗

Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variantsSemantic proximity Read ↗

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.Semantic proximity Read ↗

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinerySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.